Recommended taking time and treatment schedule for talquetamab-tgvs

Talquetamab is a new immunotherapy drug used to treat certain types of blood cancers, particularly multiple myeloma. It regulates the immune system by targeting GPRC5D (G protein-coupled receptor) and promotes the body's immune cells to attack tumor cells. In order to maximize the therapeutic effect and reduce adverse reactions, the dosage time and treatment schedule of taquitumab need to be strictly in accordance with the recommended protocol.

Taquitumab is administered by subcutaneous injection, and different ascending dose regimens are adopted according to the specific conditions of the patient. In order to reduce the incidence of cytokine release syndrome (CRS), patients need to receive certain monitoring during treatment. The following are the specific medication recommendations and treatment schedule for Taquitumab:

1. Suggested taking time and treatment schedule

There are two main dosing regimens for taquitumab: weekly and biweekly. Which option is chosen depends primarily on the patient's physical response and the specific recommendations of the doctor.

Weekly dosing schedule: The ascending doses of this schedule include 0.01 mg/kg on day 1, 0.06 mg/kg on day 4, and 0.4 mg/kg on day 7. Thereafter, patients will receive a weekly subcutaneous injection of 0.4 mg/kg. This protocol is suitable for patients who are new to the drug in order to gradually increase the dose and reduce the adverse effects caused by the drug. Within 48 hours after the first dose, the patient needs to be hospitalized for observation in order to promptly deal with any adverse reactions that may occur.

Every two-week dosing schedule: This schedule is suitable for patients who have good tolerance to the drug. The incremental dosage includes 0.01 mg/kg on day 1, 0.06 mg/kg on day 4, 0.4 mg/kg on day 7, 0.8 mg/kg on day 10, and then subcutaneous injection of 0.8 mg/kg every two weeks. The biweekly dosing schedule is usually suitable for patients who have achieved certain results through initial treatment. It can reduce the patient's treatment burden and maintain the sustained effect of the drug.

2. Recommended pretreatment drugs

To minimize the risk of cytokine release syndrome (CRS) that may occur during treatment, patients need to take some pre-treatment medications before receiving Taquitutumab. These drugs can effectively alleviate the side effects caused by drugs and ensure a smoother treatment process.

1)Corticosteroids: Patients need to take 16 mg of dexamethasone or an equivalent dose of another corticosteroid 1-3 hours before each dose. Corticosteroids help suppress the immune system's overreaction, thereby reducing the occurrence of CRS.

2) Antihistamines: Taking50 mg of diphenhydramine (or an equivalent dose of other antihistamines) can help relieve allergic reactions caused by drugs.

3) Fever-reducing drugs: Before treatment, patients should take650-1000mg acetaminophen (or equivalent doses of other antipyretics) to reduce possible fever symptoms.

Patients need to note that the administration time and dosage of the drug should be adjusted according to the doctor's guidance, especially in the case of adverse reactions. If cytokine release syndrome or other serious adverse reactions occur during treatment, the drug may need to be suspended and the treatment plan adjusted according to the specific situation.

3. Treatment course monitoring and adjustment

The treatment schedule of Taquitumab is not static. During the treatment process, patients need to be monitored regularly to ensure that the effect of the drug is maximized and possible side effects are detected in a timely manner. If the patient experiences significant adverse reactions during the dose escalation phase, treatment may be delayed or the dose may be reduced. In addition, patients should also undergo regular physical examinations and blood tests based on the doctor's recommendations to ensure the safety of treatment.

Reference materials:https://www.talveyhcp.com/